Caplin Point Laboratories Ltd Quarterly Results
Q3 FY25-26 Results Summary
Revenue
The revenue stands at ₹542.77 crore, reflecting a quarter-on-quarter *(QoQ) increase of 1.63 per cent from ₹534.04 crore. This corresponds to a year-on-year *(YoY) growth of 10.10 per cent.
Operating Profit
Operating Profit stands at ₹189.67 crore, reflecting a quarter-on-quarter *(QoQ) increase of 0.26 per cent from ₹189.17 crore. This corresponds to a year-on-year *(YoY) growth of 16.88 per cent.
PBDT
PBDT stands at ₹223.17 crore, reflecting a quarter-on-quarter *(QoQ) increase of 1.72 per cent from ₹219.40 crore. This corresponds to a year-on-year *(YoY) growth of 15.36 per cent.
Profit Before Tax
Profit Before Tax stands at ₹203.89 crore, reflecting a quarter-on-quarter *(QoQ) increase of 1.44 per cent from ₹201.00 crore. This corresponds to a year-on-year *(YoY) growth of 15.02 per cent.
Net Profit
Net Profit stands at ₹165.86 crore, reflecting a quarter-on-quarter *(QoQ) increase of 3.51 per cent from ₹160.23 crore. This represents a 18.41 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Market News
Caplin Point Laboratories Ltd Earnings
- YOY
- QOQ
Caplin Point Laboratories Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Caplin Point Laboratories Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Caplin Point Laboratories Ltd Financial Reports
Caplin Point Laboratories Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Caplin Point Lab | -1.20% | -0.69% | 8.34% | -5.57% | -16.14% | -9.52% |
| Rubicon Research | -0.20% | 3.37% | 24.33% | 43.15% | 56.90% | 54.64% |
| Alembic Pharma | -1.08% | 0.31% | 11.42% | -4.08% | -15.97% | -14.09% |
| Jubilant Pharmo | 0.19% | -1.74% | 13.66% | -3.87% | -15.45% | 2.32% |
| Alivus Life | 2.16% | -2.25% | 4.32% | 12.15% | 13.36% | -5.70% |
| Concord Biotech | 0.72% | 12.22% | 11.70% | -0.02% | -20.98% | -23.66% |
| Sanofi Consumer | -1.59% | 3.66% | 4.82% | 11.87% | -1.16% | -3.61% |
Company Info
Company Information
Chairman & Non Executive Dir. : C C Paarthipan
Non Independent Executive Director / MD : Sridhar Ganesan
Independent Non Exe. Director : R Vijayaraghavan
Independent Non Exe. Director : C K Gariyali
Independent Non Exe. Director : Deenadayalan Singaram
Independent Non Exe. Director : R Nagendran
Co. Sec. / Comp. Officer / General Counsel : VENKATRAM GANAPATHYSUBRAMANIAN
Additional Director : K C John
Vice Chairman & Additional Director : ASHOK GORKEY PARTHEEBAN
Vice Chairman & Additional Director : PARTHEEBAN VIVEK SIDDARTH